Sienna Biopharmaceuticals, Inc.
SNNAQ · OTC
12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $52 | $30 | $11 | $2 |
| G&A Expenses | $25 | $18 | $10 | $9 |
| SG&A Expenses | $25 | $18 | $10 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $76 | $49 | $21 | $11 |
| Operating Income | -$76 | -$49 | -$21 | -$11 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | -$2 | -$0 | -$0 |
| Pre-Tax Income | -$73 | -$51 | -$21 | -$11 |
| Tax Expense | -$0 | -$0 | $1 | $0 |
| Net Income | -$73 | -$51 | -$22 | -$11 |
| % Margin | – | – | – | – |
| EPS | -3.59 | -5.19 | -11.23 | -5.81 |
| % Growth | 30.8% | 53.8% | -93.3% | – |
| EPS Diluted | -3.59 | -5.19 | -11.23 | -5.81 |
| Weighted Avg Shares Out | 20 | 10 | 2 | 2 |
| Weighted Avg Shares Out Dil | 20 | 10 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$76 | -$48 | -$21 | -$11 |
| % Margin | – | – | – | – |